Clinical Trials for Other Solid Tumor

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B694, an Autologous Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors expressing Mesothelin (MSLN) and with lost HLA-A*02 expression, such as colorectal, non-small cell lung, ovarian cancer, and mesothelioma, to evaluate A2B694, an autologous logic-gated Tmod CAR T-cell therapy targeting MSLN-positive and HLA-A*02-negative cancer cells. Patients receive preconditioning lymphodepletion before the A2B694 infusion.

ClinicalTrials.gov ID: NCT06051695

A Phase 1/1b, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF6215 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is for adult patients with advanced, unresectable, recurrent, or metastatic solid tumors without standard treatment options, evaluating DF6215, a modified IL-2 immunotherapy targeting IL-2 receptors to enhance T and NK cell activation.

ClinicalTrials.gov ID: NCT06108479

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates LY4101174, an antibody-drug conjugate targeting Nectin-4, in patients with recurrent, advanced, or metastatic solid tumors such as urothelial carcinoma and triple-negative breast cancer, including those previously treated with enfortumab vedotin. Participants must have exhausted standard therapies, and the study aims to assess safety and efficacy to determine the recommended phase 2 dose.

ClinicalTrials.gov ID: NCT06238479

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced And/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial investigates NT-175, an engineered autologous T cell therapy targeting the TP53 R175H mutation, in HLA-A*02:01-positive adults with advanced or metastatic solid tumors such as NSCLC, colorectal adenocarcinoma, and breast cancer, after exhausting at least one prior treatment.

ClinicalTrials.gov ID: NCT05877599

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients aged 18 and older with advanced/metastatic solid tumors, exploring BI-1910, a monoclonal antibody targeting TNFR2 to activate T and NK cells, alone and in combination with pembrolizumab, particularly for those who have progressed after or are ineligible for standard therapies.

ClinicalTrials.gov ID: NCT06205706

A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the combination of MRX-2843, a small molecule tyrosine kinase inhibitor targeting MERTK and FLT3, with osimertinib in patients with metastatic non-small cell lung cancer harboring EGFR mutations, focusing on safety, tolerability, and optimal dosing. Eligible patients include those with ECOG performance status 0-2 and specific genetic and biochemical profiles.

ClinicalTrials.gov ID: NCT04762199

C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial targets patients with stage IV or recurrent NSCLC resistant to anti-PD1 therapy, using a combination of C-TIL051 (engineered tumor-infiltrating lymphocytes), NKTR-255 (IL-15 receptor agonist), and Pembrolizumab to enhance immune response. Participants must have adenocarcinoma or squamous histology, measurable disease, and no prior PD1/PDL1 inhibitor treatment for metastatic disease.

ClinicalTrials.gov ID: NCT05676749

A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is enrolling patients with advanced-stage solid tumors, including HER2-mutant non-small cell lung cancer and HER2-positive metastatic breast cancer, to evaluate the safety and efficacy of ELVN-002, a novel oral tyrosine kinase inhibitor targeting HER2 and multiple HER2 mutations, as a monotherapy and in combination with standard treatments.

ClinicalTrials.gov ID: NCT05650879

A Phase 1a/1b Open-Label Study of BBO-8520 As Monotherapy and As Part of Combination Therapy in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer and Colorectal Cancer - the ONKORAS-101 Study

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The ONKORAS-101 trial involves patients with KRAS G12C mutant non-small cell lung cancer or colorectal cancer, exploring the safety and efficacy of BBO-8520, a novel KRAS G12C inhibitor, both as monotherapy and in combination with the PD-1 inhibitor pembrolizumab.

ClinicalTrials.gov ID: NCT06343402

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates dostarlimab, an anti-PD-1 monoclonal antibody, in adults with advanced solid tumors who have progressed despite prior treatments, focusing on specific cohorts such as endometrial cancer, non-small cell lung cancer, ovarian cancer, and tumors with mismatch repair deficiencies. Participants should have limited viable treatment options.

ClinicalTrials.gov ID: NCT02715284